Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MTNB | US
0.19
4.88%
Healthcare
Biotechnology
30/06/2024
17/10/2024
4.08
3.91
4.10
3.85
Matinas BioPharma Holdings Inc. a clinical-stage biopharmaceutical company focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules nucleic acids gene therapies vaccines proteins and peptides. Its lead product candidate is LYPDISO a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203 an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition it provides MAT2501 an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria including non-tuberculous mycobacterium infections as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech Inc. for the development of oral formulations. Matinas BioPharma Holdings Inc. was incorporated in 2013 and is based in Bedminster New Jersey.
View LessStrength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
Microcap (<300M USD)
High Market Beta (> 0.8)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
83.3%1 month
79.6%3 months
77.4%6 months
62.2%-
-
0.83
0.17
0.13
-1.79
37.20
-
-23.38M
20.66M
20.66M
-
-
-
-100.00
-97.59
1.22
1.28
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.14
Range1M
1.14
Range3M
4.40
Rel. volume
1.36
Price X volume
192.09K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Cyclo Therapeutics Inc | CYTH | Biotechnology | 0.7849 | 22.52M | -0.65% | n/a | -58.50% |
Pieris Pharmaceuticals Inc | PIRS | Biotechnology | 16.93 | 22.08M | 2.67% | n/a | 0.00% |
NeuroSense Therapeutics Ltd. Ordinary Shares | NRSN | Biotechnology | 1.1 | 21.79M | 12.30% | n/a | -2.11% |
HCW Biologics Inc. Common Stock | HCWB | Biotechnology | 0.56 | 21.18M | -6.67% | n/a | -159.13% |
Spruce Biosciences Inc | SPRB | Biotechnology | 0.51 | 21.06M | -1.75% | n/a | 6.24% |
Cocrystal Pharma Inc | COCP | Biotechnology | 2.04 | 20.75M | -7.27% | n/a | 10.24% |
BIOR | BIOR | Biotechnology | 0.5538 | 20.20M | -6.14% | n/a | -52.57% |
MONOPAR THERAPEUTICS | MNPR | Biotechnology | 5.71 | 20.10M | 8.56% | n/a | 0.00% |
Klotho Neurosciences Inc. | KLTO | Biotechnology | 0.59 | 20.06M | 5.06% | n/a | 0.00% |
Cadrenal Therapeutics Inc. Common Stock | CVKD | Biotechnology | 16.3 | 19.27M | 6.19% | n/a | 0.22% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.6 | 19.19M | 0.80% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 0.98 | 17.70M | -3.92% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.79 | 0.53 | Cheaper |
Ent. to Revenue | 37.20 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.83 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 77.39 | 72.92 | Par |
Debt to Equity | 0.17 | -1.24 | Expensive |
Debt to Assets | 0.13 | 0.25 | Cheaper |
Market Cap | 20.66M | 3.78B | Emerging |